Prenatal Screening for Fetal Aneuploidy in Singleton Pregnancies

Journal of Obstetrics and Gynaecology Canada

Volumn 33, Issue 7, 2011, Pages 736-750

  Chitayat, David ^a   Langlois, Sylvie ^a   Douglas Wilson, R ^a,a   Audibert, François ^a   Blight, Claire ^a   Brock, Jo Ann ^a   Cartier, Lola ^a   Carroll, June ^a   Désilets, Valerie A ^a   Gagnon, Alain ^a   Johnson, Jo Ann ^a   Murphy Kaulbeck, Lynn ^a   Okun, Nanette ^a   Pastuck, Melanie ^a   Senikas, Vyta ^a   DeBie, Isabelle ^a   Demczuk, Suzanne ^a   Desilets, Valerie A ^a   Geraghty, Michael T ^a   Marcadier, Janet ^a   Nelson, Tanya N ^a   Skidmore, David ^a   Siu, Vicky ^a   more..

^a Calgary ^*  (Canada)

Author keywords

Aneuploidy; Down syndrome; Genetic health risk; Genetic health surveillance; Prenatal diagnosis; Prenatal screening; Trisomy

Indexed keywords

ANEUPLOIDY; ARTICLE; BIOCHEMISTRY; BIOMEDICAL TECHNOLOGY ASSESSMENT; BLOOD ANALYSIS; CANADA; CHROMOSOME ABERRATION; CHROMOSOME REARRANGEMENT; CONSENSUS DEVELOPMENT; CYTOGENETICS; DISEASE SURVEILLANCE; DOWN SYNDROME; FERTILIZATION IN VITRO; FETUS DISEASE; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; GYNECOLOGIST; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; INVASIVE PROCEDURE; MATERNAL AGE; NON INVASIVE PROCEDURE; NUCHAL TRANSLUCENCY MEASUREMENT; OBSERVATIONAL STUDY; OBSTETRICIAN; PRACTICE GUIDELINE; PRENATAL SCREENING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; SYSTEMATIC REVIEW (TOPIC); TRISOMY; TRISOMY 13; TRISOMY 18; TRISOMY 21; ADULT; BLOOD; CHROMOSOME 18; FEMALE; GESTATIONAL AGE; LITERATURE; METHODOLOGY; PREGNANCY; PRENATAL DIAGNOSIS; RISK FACTOR;

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ALPHA-FETOPROTEINS; ANEUPLOIDY; BIOLOGICAL MARKERS; CANADA; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; CHROMOSOMES, HUMAN, PAIR 18; DOWN SYNDROME; FEMALE; GENETIC TESTING; GESTATIONAL AGE; HUMANS; MATERNAL AGE; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVIEW LITERATURE AS TOPIC; RISK FACTORS; TRISOMY; ULTRASONOGRAPHY, PRENATAL;

EID: 82355181830     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)34961-1     Document Type: Article

References (106)

1. Woolf S.H., Battista R.N., Angerson G.M., Logan A.G. Eel W Canadian Task Force on Preventive Health Care. New grades for recommendations from the Canadian Task Force on Preventive Health Care. CMAJ 2003, 169:207-208.
2. Cuckle H.S., Wald N. Tests using single markers. Antenatal and neonatal screening 2000, 3-19. Oxford University Press, Oxford. N. Wald, I. Leck (Eds.).
3. Resta R.G. Changing demographics of advanced maternal age (AMA) and the impact on the predicted incidence of Down syndrome in the United States: implications for prenatal screening and genetic counseling. Am J Med Genet A 2005, 133:31-36.
4. Bonduelle M., Van Assche E., Joris H., Keymolen K., Devroey P., Van Steirteghem A., et al. Prenatal testing in ICSI pregnancies: incidence of chromosomal anomalies in 1586 karyotypes and relation to sperm parameters. Hum Reprod 2002, 17:2600-2614.
5. Wald N.J., Rodeck C., Hackshaw A.K., Walters J., Chitty L., Mackinson A.M. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003, 10:56-104.
6. Odibo A.O., Stamilio D.M., Nelson D.B., Sehdev H.M., Macones G.A. A Cost-effectiveness analysis of prenatal screening strategies for Down syndrome. Obstet Gynecol 2005, 106:562-568.
7. Vintzileos A.M., Ananth C.V., Smulian J.C., Day-Salvatore D.L., Beazoglou T., Knuppel R.A. Cost-benefit analysis of prenatal diagnosis for Down syndrome using the British or the American approach. Obstet Gynecol 2000, 95:577-583.
8. Caughey A.B., Kuppermann M., Norton M.E., Washington A.E. Nuchal translucency and first trimester biochemical markers for Down syndrome screening: a cost-effectiveness analysis. Am J Obstet Gynecol 2002, 187:1239-1245.
9. Biggio J.R., Morris T.C., Owen J., Stringer J.S. An outcomes analysis of five prenatal screening strategies for trisomy 21 in women younger than 35 years. Am J Obstet Gynecol 2004, 190:721-729.
10. Malone F.D., Canick J.A., Ball R.H., Nyberg D.A., Comstock C.H., Bukowski R., et al. First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005, 353:2001-2011.
11. Wald N.J., Kennard A., Hackshaw A., McGuire A. Antenatal screening for Down's syndrome. J Med Screen 1997, 4:181-246.
12. Summers A.M., Farrell S.A., Huang T., Meier C., Wyatt P.R. Maternal serum screening in Ontario using the triple marker test. J Med Screen 2003, 10:107-111.
13. Bishop A.J., Marteau T.M., Armstrong D., Chitty L.S., Longworth L., Buxton M.J., et al. Women and health care professionals' preferences for Down's syndrome screening tests: a conjoint analysis study. BJOG 2004, 111:775-779.
14. Lee C.P., Tang M., Tang R., Tse H.Y., Woo H., To W.K., et al. Acceptability of first and second trimester screening for fetal Down's syndrome-interim results from a demonstration trial 2004, Abstract 71.
15. Carroll J.C., Reid A.J., Woodward C.A., Permaul-Woods J.A., Domb S., Ryan G., et al. Ontario Maternal Serum Screening Program: practices, knowledge and opinions of health care providers. CMAJ 1997, 156:775-784.
16. Spencer K., Aitken D. Factors affecting women's preference for type of prenatal screening test for chromosomal anomalies. Ultrasound Obstet Gynecol 2004, 24:735-739.
17. Mulvey S., Zachariah R., McIlwaine K., Wallace E.M. Do women prefer to have screening tests for Down syndrome that have the lowest screen-positive rate or the highest detection rate?. Prenat Diagn 2003, 23:828-832.
18. Nicolaides K.H., Azar G., Byrne D., Mansur C., Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ 1992, 304:867-869.
19. Wapner R., Thom E., Simpson J.L., Pergament E., Silver R., Filkins K., et al. First-trimester screening for trisomies 21 and 18. N Engl J Med 2003, 349:1405-1413.
20. Makrydimas G., Sotiriadis A., Ioannidis J.P. Screening performance of first-trimester nuchal translucency for major cardiac defects: a meta-analysis. Am J Obstet Gynecol 2003, 189:1330-1335.
21. Souka A.P., Snijders R.J., Novakov A., Soares W., Nicolaides K.H. Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10-14 weeks of gestation. Ultrasound Obstet Gynecol 1998, 11:391-400.
22. Macri J.N., Spencer K., Aitken D., Garver K., Buchanan P.D., Muller F., et al. First-trimester free beta (hCG) screening for Down syndrome. Prenat Diagn 1993, 13:557-562.
23. Orlandi F., Damiani G., Hallahan T.W., Krantz D.A., Macri J.N. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency. Ultrasound Obstet Gynecol 1997, 10:381-386.
24. Wald N.J., Hackshaw A.K. Combining ultrasound and biochemistry in firsttrimester screening for Down's syndrome. Prenat Diagn 1997, 17:821-829.
25. Snijders R.J., Thom E.A., Zachary J.M., Platt L.D., Greene N., Jackson L.G., et al. First-trimester trisomy screening; nuchal translucency measurement training and quality assurance to correct and unify technique. Ultrasound Obstet Gynecol 2002, 19:353-359.
26. Recommendations of the 32nd Study Group of the College of Obstetricians and Gynecologist. Screening for Down's syndrome in the first trimester 1997, 353-356. RCOG Press, London. J.G. Grudzinskas, R.H.T. Ward (Eds.).
27. Evans M.I., Pergament E. Impact of quality of nuchal translucency measurements on detection rates of trisomies 13 and 18. Fetal Diagn Ther 2010, 27:68-71.
28. Cicero S., Curcio P., Papageorghiou A., Sonek J., Nicolaides K. Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study. Lancet 2001, 358:1665-1667.
29. Cicero S., Rembouskos G., Vandecruys H., Hogg M., Nicolaides K.H. Likelihood ratio for trisomy 21 in fetuses with absent nasal bone at the 11-14-week scan. Ultrasound Obstet Gynecol 2004, 23:218-223.
30. Malone F.D., Ball R.H., Nyberg D.A., Comstock C.H., Saade G., Berkowitz R.L., et al. First-trimester nasal bone evaluation for aneuploidy in the general population. Obstet Gynecol 2004, 104:1222-1228.
31. Senat M.V., Bernard J.P., Boulvain M., Ville Y. Intra- and interoperator variability in fetal nasal bone assessment at 11-14 weeks of gestation. Ultrasound Obstet Gynecol 2003, 22:138-141.
32. Merkatz I.R., Nitowsky H.M., Macri J.N., Johnson W.E. An association between low maternal serum alpha-fetoprotein and fetal chromosome anomalies. Am J Obstet Gynecol 1984, 148:886-894.
33. Wald N.J., Cuckle H.S., Denssem J.W., Nanchahal K., Haddow J.E., Knight G.J., et al. Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988, 297:883-887.
34. Haddow J.E., Palomaki G.E., Knight G.J., Williams J., Miller W.A., Johnson A. Screening of maternal serum for fetal Down's syndrome in the first trimester. N Engl J Med 1998, 338:955-961.
35. Lambert-Messerlian G.M., Canick J.A., Palomaki G.E., Schneyer A.L. Second trimester levels of maternal serum inhibin A, total inhibin, alpha inhibin precursor, and activin in Down's syndrome pregnancy. J Med Screen 1996, 3:58-62.
36. Wald N.J., Densem J.W., George L., Muttukrishna S., Knight P.G. Prenatal screening for Down's syndrome using inhibin-A as a serum marker. Prenat Diagn 1996, 6:143-153.
37. Wald N.J., Watt H.C., Hackshaw A.K. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med 1999, 341:461-467.
38. Copel J.A., Bahado-Singh R.O. Prenatal screening for Down's syndrome-a search for the family's values. N Engl J Med 1999, 341:521-522.
39. Wright D., Bradbury I., Benn P., Cuckle H., Ritchie K. Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening. Prenat Diagn 2004, 24:762-766.
40. Benn P., Wright D., Cuckle H. Practical strategies in contingent sequential screening for Down syndrome. Prenat Diagn 2005, 25:645-652.
41. Palomaki G.E., Steinort K., Knight G.J., Haddow J.E. Comparing three screening strategies for combining first- and second- trimester Down syndrome markers. Obstet Gynecol 2006, 107:367-375.
42. Wald N.J., Rudnicka A.R., Bestwick J.P. Sequential and contingent prenatal screening for Down syndrome. Prenat Diagn 2006, 26:769-777.
43. Gekas J., Gagne G., Bujold E., Douillard D., Forest J.-C., Reinharz D., Rousseau F. Comparison of different strategies in prenatal screening for Down's syndrome: cost effectiveness analysis of computer simulation. BMJ 2009, 338:b138.
44. Cocciolone R., Brameld K., O'Leary P., Haan E., Muller P., Shand K. Combining first and second trimester markers for Down syndrome screening: think twice. Aust N Z Obstet Gynaecol 2008, 48:492-500.
45. Summers A.M., Huang T., Meier C., Farrell S.A. Contingent screening for Down syndrome. Prenat Diagn 2005, 25:963-964.
46. Kadir R.A., Economides D.L. The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome. Ultrasound Obstet Gynecol 1997, 9:244-247.
47. Platt L.D., Greene N., Johnson A., Zachary J., Thom E., Krantz D., et al. Sequential pathways of testing after first-trimester screening for trisomy 21. Obstet Gynecol 2004, 104:661-666.
48. Canick J.A., Palomaki G.E., Osathanondh R. Prenatal screening for trisomy 18 in the second trimester. Prenat Diagn 1990, 10:546-548.
49. Lambert-Messerlian G.M., Saller D.N., Tumber M.B., French C.A., Peterson C.J., Canick J.A. Second-trimester maternal serum progesterone levels in Turner syndrome with and without hydrops and in trisomy 18. Prenat Diagn 1999, 19:476-479.
50. Bersinger N.A., Brizot M.L., Johnson A., Snijders R.J., Abbott J., Schneider H., et al. First trimester maternal serum pregnancy-associated plasma protein A and pregnancy-specific beta 1-glycoprotein in fetal trisomies. Br J Obstet Gynaecol 1994, 101:970-974.
51. Sherod C., Sebire N.J., Soares W., Snijders R.J., Nicolaides K.H. Prenatal diagnosis of trisomy 18 at the 10-14-week ultrasound scan. Ultrasound Obstet Gynecol 1997, 10:387-390.
52. Palomaki G.E., Haddow J.E., Knight G.J., Wald N.J., Kennard A., Canick J.A., et al. Risk-based prenatal screening for trisomy 18 using alpha-fetoprotein, unconjugated oestriol and human chorionic gonadotropin. Prenat Diagn 1995, 15:713-723.
53. Palomaki G.E., Neveux L.M., Knight G.J., Haddow J.E. Maternal serum-integrated screening for trisomy 18 using both first- and second-trimester markers. Prenat Diagn 2003, 23:243-247.
54. Spencer K., Nicolaides K.H. A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A. Prenat Diagn 2002, 22:877-879.
55. Spencer K., Liao A.W., Skentou H., Cicero S., Nicolaides K.H. Screening for triploidy by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 2000, 20:495-499.
56. Huang T., Alberman E., Wald N., Summers A.M. Triploidy identified through second-trimester serum screening. Prenat Diagn 2005, 25:229-233.
57. Saller D.N., Canick J.A., Blitzer M.G., Palomaki G.E., Schwartz S., Blakemore K.J., et al. Second-trimester maternal serum analyte levels associated with fetal trisomy 13. Prenat Diagn 1999, 19:813-816.
58. Cuckle H.S., Sehmi I.K., Jones R.G. Inhibin A and non-Down syndrome aneuploidy. Prenat Diagn 1999, 19:787-788.
59. Saller D.N., Canick J.A., Schwartz S., Blitzer M.G. Multiple-marker screening in pregnancies with hydropic and nonhydropic Turner syndrome. Am J Obstet Gynecol 1992, 167:1021-1024.
60. Laundon C.H., Spencer K., Macri J.N., Anderson R.W., Buchanan P.D. Free beta hCG screening of hydropic and non-hydropic Turner syndrome pregnancies. Prenat Diagn 1996, 16:853-856.
61. Lambert-Messerlian G.M., Saller D.N., Tumber M.B., French C.A., Peterson C.J., Canick J.A. Second-trimester maternal serum inhibin A levels in fetal trisomy 18 and Turner syndrome with and without hydrops. Prenat Diagn 1998, 18:1061-1067.
62. Snijders R.J., Sebire N.J., Nayar R., Souka A., Nicolaides K.H. Increased nuchal translucency in trisomy 13 fetuses at 10-14 weeks of gestation. Am J Med Genet 1999, 86:205-207.
63. Spencer K., Ong C., Skentou H., Liao A.W., Nicolaides K.H. Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 2000, 20:411-416.
64. Spencer K., Tul N., Nicolaides K.H. Maternal serum free beta-hCG and PAPP-A in fetal sex chromosome defects in the first trimester. Prenat Diagn 2000, 20:390-394.
65. Ryan A.K., Bartlett K., Clayton P., Eaton S., Mills L., Donnai D., et al. Smith-Lemli-Opitz syndrome: a variable clinical and biochemical phenotype. J Med Genet 1998, 35:558-565.
66. Irons M., Elias E.R., Salen G., Tint G.S., Batta A.K. Defective cholesterol biosynthesis in Smith-Lemli-Opitz syndrome. Lancet 1993, 341:1414.
67. Tint G.S., Abuelo D., Till M., Cordier M.P., Batta A.K., Shefer S., et al. Fetal Smith-Lemli-Opitz syndrome can be detected accurately and reliably by measuring amniotic fluid dehydrocholesterols. Prenat Diagn 1998, 18:651-658.
68. Bradley L.A., Palomaki G.E., Knight G.J., Haddow J.E., Opitz J.M., Irons M., et al. Levels of unconjugated estriol and other maternal serum markers in pregnancies with Smith-Lemli-Opitz (RSH) syndrome fetuses. Am J Med Genet 1999, 82:355-358.
69. Palomaki G.E., Bradley L.A., Knight G.J., Craig W.Y., Haddow J.E. Assigning risk for Smith-Lemli-Opitz syndrome as part of 2nd trimester screening for Down's syndrome. J Med Screen 2002, 9:43-44.
70. Kashork C.D., Sutton V.R., Fonda Allen J.S., Schmidt D.E., Likhite M.L., Potocki L., et al. Low or absent unconjugated estriol in pregnancy: an indicator for steroid sulfatase deficiency detectable by fluorescence in situ hybridization and biochemical analysis. Prenat Diagn 2002, 22:1028-1032.
71. Van den Hof M.C., Demianczuk N. SOGC Diagnostic Imaging Committee. Content of a Complete Obstetrical Report. SOGC Committee Opinion No. 103, May 2001. J Soc Obstet Gynaecol Can 2001, 23:427-428.
72. Van den Hof M.C., Nicolaides H., Campbell J., Campbell S. Evaluation of the lemon and banana signs in one hundred thirty fetuses with open spina bifida. Am J Obstet Gynecol 1990, 162:322-327.
73. Smith-Bindman R., Hosmer W., Feldstein V.A., Deeks J.J., Goldberg J.D. Second-trimester ultrasound to detect fetuses with Down syndrome: a meta-analysis. JAMA 2001, 285:1044-1055.
74. Nyberg D.A., Souter V.L., El-Bastawissi A., Young S., Luthhardt F., Luthy D.A. Isolated sonographic markers for detection of fetal Down syndrome in the second trimester of pregnancy. J Ultrasound Med 2001, 20:1053-1063.
75. Viora E., Errante G., Bastonero S., Sciarrone A., Campogrande M. Minor sonographic signs of trisomy 21 at 15-20 weeks' gestation in fetuses born without malformations: a prospective study. Prenat Diagn 2001, 21:1163-1166.
76. Lamont R.F., Havutcu E., Salgia S., Adinkra P., Nicholl R. The association between isolated fetal echogenic cardiac foci on second-trimester ultrasound scan and trisomy 21 in low-risk unselected women. Ultrasound Obstet Gynecol 2004, 23:346-351.
77. Van den Hof M.C., Wilson R.D. SOGC Diagnostic Imaging Committee; SOGC Genetics Committee. Fetal soft markers in obstetric ultrasound. SOGC Clinical Practice Guideline No. 162, June 2005. J Obstet Gynaecol Can 2005, 27:592-636.
78. Vintzileos A.M., Guzman E.R., Smulian J.C., Day-Salvatore D.L., Knuppel R.A. Indication-specific accuracy of second-trimester genetic ultrasonography for the detection of trisomy 21. Am J Obstet Gynecol 1999, 181:1045-1048.
79. Bromley B., Lieberman E., Shipp T.D., Benacerraf B.R. The genetic sonogram. A method of risk assessment for Down syndrome in the second trimester. J Ultrasound Med 2002, 21:1087-1096.
80. Nyberg D.A., Luthy D.A., Resta R.G., Nyberg B.C., Williams M.A. Age-adjusted ultrasound risk assessment for fetal Down's syndrome during the second trimester: description of the method and analysis of 142 cases. Ultrasound Obstet Gynecol 1998, 12:8-14.
81. Sohl B.D., Scioscia A.L., Budorick N.E., Moore T.R. Utility of minor ultrasonographic markers in the prediction of abnormal fetal karyotype at a prenatal diagnostic center. Am J Obstet Gynecol 1999, 181:898-903.
82. Aagaard-Tillery K.M., Malone F.D., Nyberg D.A., Porter T.F., Cuckle H.S., Fuchs K., et al. Role of second-trimester genetic sonography after Down syndrome screening. Obstet Gynecol 2009, 114:1189-1196.
83. Smith-Bindman R., Chu P., Goldberg J.D. Second trimester prenatal ultrasound for the detection of pregnancies at increased risk of Down syndrome. Prenat Diagn 2007, 27:535-544.
84. Neveux L.M., Palomaki G.E., Larrivee D.A., Knight G.J., Haddow J.E. Refinements in managing maternal weight adjustment for interpreting prenatal screening results. Prenat Diagn 1996, 16:1115-1119.
85. de Graaf I.M., Cuckle H.S., Pajkrt E., Leschot N.J., Bleker O.P., van Lith J.M. Co-variables in first trimester maternal serum screening. Prenat Diagn 2000, 20:186-189.
86. Krantz D.A., Hallahan T.W., Macri V.J., Macri J.N. Maternal weight and ethnic adjustment within a first-trimester Down syndrome and trisomy 18 screening program. Prenat Diagn 2005, 25:635-640.
87. Watt H.C., Wald N.J., Smith D., Kennard A., Densem J. Effect of allowing for ethnic group in prenatal screening for Down's syndrome. Prenat Diagn 1996, 16:691-698.
88. Spencer K., Ong C.Y., Liao A.W., Nicolaides K.H. The influence of ethnic origin on first trimester biochemical markers of chromosomal abnormalities. Prenat Diagn 2000, 20:491-494.
89. Huang T., Summers A.M., Wyatt P.R., Meier C., Cote G.B. Maternal serum marker medians in Aboriginal Canadian women. Prenat Diagn 2003, 23:98-100.
90. Spencer K., Heath V., El-Sheikhah A., Ong C.Y., Nicolaides K.H. Ethnicity and the need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first trimester: a study of Oriental, Asian and Afro-Caribbean populations. Prenat Diagn 2005, 25:365-369.
91. Thilaganathan B., Khare M., Williams B., Wathen N.C. Influence of ethnic origin on nuchal translucency screening for Down's syndrome. Ultrasound Obstet Gynecol 1998, 12:112-114.
92. Chen M., Lam Y.H., Tang M.H., Lee C.P., Sin S.Y., Tang R., et al. The effect of ethnic origin on nuchal translucency at 10-14 weeks of gestation. Prenat Diagn 2002, 22:576-578.
93. Palomaki G.E., Knight G.J., Haddow J.E. Human chorionic gonadotropin and unconjugated oestriol measurements in insulin-dependent diabetic pregnant women being screened for fetal Down syndrome. Prenat Diagn 1994, 14:65-68.
94. Huttly W., Rudnicka A., Wald N.J. Second-trimester prenatal screening markers for Down syndrome in women with insulin-dependent diabetes mellitus. Prenat Diagn 2004, 24:804-807.
95. Spencer K., Cicero S., Atzei A., Otigbah C., Nicolaides K.H. The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy. Prenat Diagn. 2005, 25:927-929.
96. Barkai G., Goldman B., Ries L., Chaki R., Dor J., Cuckle H. Down's syndrome screening marker levels following assisted reproduction. Prenat Diagn 1996, 16:1111-1114.
97. Wald N.J., White N., Morris J.K., Huttly W.J., Canick J.A. Serum markers for Down's syndrome in women who have had in vitro fertilisation: implications for antenatal screening. Br J Obstet Gynaecol 1999, 106:1304-1306.
98. Perheentupa A., Ruokonen A., Tuomivaara L., Ryynanen M., Martikainen H. Maternal serum beta-HCG and alpha-fetoprotein concentrations in singleton pregnancies following assisted reproduction. Hum Reprod 2002, 17:794-797.
99. Raty R., Virtanen A., Koskinen P., Anttila L., Forsstrom J., Laitinen P., et al. Serum free beta-HCG and alpha-fetoprotein levels in IVF, ICSI and frozen embryo transfer pregnancies in maternal mid-trimester serum screening for Down's syndrome. Hum Reprod 2002, 17:481-484.
100. Maymon R., Shulman A. Serial first-and second-trimester Down's syndrome screening tests among IVF-versus naturally-conceived singletons. Hum Reprod 2002, 17:1081-1085.
101. Maymon R., Shulman A. Integrated first- and second-trimester Down syndrome screening test among unaffected IVF pregnancies. Prenat Diagn 2004, 24:125-129.
102. Muller F., Dreux S., Lemeur A., Sault C., Desgres J., Bernard M.A., et al. French Collaborative Group. Medically assisted reproduction and second- trimester maternal serum marker screening for Down syndrome. Prenat Diagn 2003, 23:1073-1076.
103. Liao A.W., Heath V., Kametas N., Spencer K., Nicolaides K.H. First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction. Hum Reprod 2001, 16:1501-1504.
104. Orlandi F., Rossi C., Allegra A., Krantz D., Hallahan T., Orlandi E., et al. First trimester screening with free beta-hCG, PAPP-A and nuchal translucency in pregnancies conceived with assisted reproduction. Prenat Diagn 2002, 22:718-721.
105. Bellver J., Lara C., Soares S.R., Ramirez A., Pellicer A., Remohi J., et al. First trimester biochemical screening for Down's syndrome in singleton pregnancies conceived by assisted reproduction. Hum Reprod 2005, 20:2623-2627.
106. Hui P.W., Tang M.H., Lam Y.H., Yeung W.S., Ng E.H., Ho P.C. Nuchal translucency in pregnancies conceived after assisted reproduction technology. Ultrasound Obstet Gynecol 2005, 25:234-238.